Zydus receives approval from China's NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.

Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). They help restore the balance of serotonin and norepinephrine in the brain to improve mood and reduce anxiety. Venlafaxine ER Capsules will be produced at Zydus' manufacturing facility at Moraiya, Ahmedabad.

This is the first approval that the Group has received from NMPA in China.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 951.20 as compared to the previous close of Rs. 938.05. The total number of shares traded during the day was 13573 in over 948 trades.

The stock hit an intraday high of Rs. 957.50 and intraday low of 938.05. The net turnover during the day was Rs. 12904145.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals China Approval Venlafaxine ExtendedReleaseCapsules